Maarten van der Doelen

Impact of DNA damage repair defects on response to radium-223 therapy in mCRPC patients

ACKNOWLEDGEMENTS

We thank the Center of Personalised Cancer Treatment and Foundation Medicine for sequencing tissue samples.

FUNDING This research was funded by Bayer The Netherlands. The funding organization had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, and writing of the report. This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation and the Center of Personalised Cancer Treatment have made available to the study.

7

189